Susquehanna International Group
ANIX icon

Susquehanna International Group’s Anixa Biosciences ANIX Stock Holding History

Susquehanna International Group’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.2K Buy
34,200
+14,000
+69% +$41.5K ﹤0.01% 12412
2025
Q4 		$63K Buy
+20,200
New +$82.7K ﹤0.01% 11673
2024
Q1 		– Sell
-11,800
Closed -$45.8K – 12098
2023
Q4 		$45.8K Sell
11,800
-26,000
-69% -$87.7K ﹤0.01% 11743
2023
Q3 		$124K Buy
37,800
+11,600
+44% +$40.6K ﹤0.01% 10741
2023
Q2 		$83.8K Buy
+26,200
New +$101K ﹤0.01% 11075
2023
Q1 		– Sell
-18,800
Closed -$79.9K – 12501
2022
Q4 		$79.9K Buy
+18,800
New +$90.4K ﹤0.01% 11126
2022
Q3 		– Sell
-15,400
Closed -$47K – 13102
2022
Q2 		$47K Sell
15,400
-8,700
-36% -$27.4K ﹤0.01% 12007
2022
Q1 		$66K Buy
24,100
+7,800
+48% +$22.9K ﹤0.01% 12160
2021
Q4 		$48K Buy
16,300
+3,200
+24% +$12.9K ﹤0.01% 12564
2021
Q3 		$62K Buy
13,100
+800
+7% +$3.61K ﹤0.01% 12272
2021
Q2 		$48K Buy
+12,300
New +$52.4K ﹤0.01% 12306

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Susquehanna International Group's ANIX Position: Q1 2026 in Review

Susquehanna International Group reduced its Anixa Biosciences (ANIX) stake by 61% in Q1 2026, selling an estimated $452K and leaving 99,468 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #11211.

Susquehanna International Group first reported a position in ANIX in Q3 2015 and has held it in 20 quarters since. The position peaked at $1.06M in Q1 2024. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Susquehanna International Group held 99,468 shares of Anixa Biosciences worth $257K as of Q1 2026.
  • Susquehanna International Group sold 152,606 Anixa Biosciences shares in Q1 2026, an estimated $452K.
  • Anixa Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11211 holding.
  • Susquehanna International Group first reported a position in Anixa Biosciences in Q3 2015 and has held it in 20 quarters since.
  • Susquehanna International Group's Anixa Biosciences position peaked at $1.06M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.